Osteogenezis imperfekta tedavisinde yenilikler ve pamidronat tedavisi
Journal Name:
- Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi
Publication Year:
- 2008
Key Words:
Keywords (Original Language):
Author Name | University of Author | Faculty of Author |
---|---|---|
REFERENCES
1. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine 2005;72:313-8.
2. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363(24):1377-85.
3. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
4. Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Efficacy of oral alendronate in children with osteogenesis imperfecta. J PediatrOrthop 2005;25:607-12.
5. Marini JC. Osteogenesis imperfecta. In: Behrman RE, Kliegman RM.Jenson HB. (eds). Nelson textbook of pediatrics. (17th ed). Saunders Philadelphia2004;2336-38.
6. Robertson WW. Orthopedics. In: MacDonald MG, Seshia MMK, Mullett MD (eds). Avery's neonatology pathophysiology & management of the newborn. Lippincott Williams & Wilkins Philadelphia 2005:1428¬43.
7. Sillence DO, Senn A, Danks DM. Genetic heterogenity in osteogenesis imperfecta. J Med Genet 1979;16:101-
16.
8. Vyskocil V, Pikner R, Kutilek S. Effect ofalendronate therapy in children with osteogenesis imperfecta Joint Bone Spine 2005;72:416-23.
9. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002;25:593-95.
10. Millington-Ward S, McMahon HP, Farrar GJ. Emerging therapeutic approaches for
osteogenesis imperfecta. Trends in Molecular Medicine 2005;11(6):299-305.
11. Whyte MP. Osteogenesis imperfecta. In: Favus MJ (editor). Primer on the metabolic bone diseases and disorders ofmineral metabolisms. (4th ed). Lippincott Williams & Wilkins Philadelphia 1999:386-89.
12. Devogelaer JP, Malghem J, Maldague B, Nagant dD. Radiological manifestations of bisphosphonate treatment with ADP in a child suffering from osteogenesisimperfecta. SkeletalRadiol 1987;16:360-
63.
13. Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta typeV.Bone2005:1-8.
14. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-50.
15. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA. Bisphosphonate treatment ofpediatric bone disease. Ped. Endocrinol. Rev. 2005;2:87-96.